Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Glioma 1

Interventions

Cyclophosphamide 78fludarabine phosphate 77Azacitidine 76Peripheral Blood Stem Cell Transplantation 63Busulfan 53Mycophenolic Acid 51Whole-Body Irradiation 50Tacrolimus 48Cytarabine 43Cyclosporine 43Methotrexate 37Decitabine 36Filgrastim 32Antilymphocyte Serum 30venetoclax 27Radiotherapy 25Melphalan 23fludarabine 22Etoposide 18Methylprednisolone 17Biopsy 15Cyclosporins 14Specimen Handling 13Injections 13Granulocyte Colony-Stimulating Factor 13Flow Cytometry 13Cord Blood Stem Cell Transplantation 13decitabine and cedazuridine drug combination 12Idarubicin 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × orludodstat × Clear all
NCT03404726 2022-01-11

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Bayer

Phase 1 Terminated
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡